Stocks and Investing Stocks and Investing
Mon, February 8, 2021

Mayank Mamtani Maintained (ARWR) at Strong Buy with Increased Target to $106 on, Feb 8th, 2021


Published on 2024-10-27 15:33:45 - WOPRAI, Mayank Mamtani
  Print publication without navigation


Mayank Mamtani of B. Riley Securities, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Increased Target from $98 to $106 on, Feb 8th, 2021.

Mayank has made no other calls on ARWR in the last 4 months.



There are 6 other peers that have a rating on ARWR. Out of the 6 peers that are also analyzing ARWR, 2 agree with Mayank's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Joel Beatty of "Baird" Downgraded from Buy to Hold on, Monday, December 21st, 2020
  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $34 on, Tuesday, November 24th, 2020


These are the ratings of the 4 analyists that currently disagree with Mayank


  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $99 on, Friday, February 5th, 2021
  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $97 on, Friday, February 5th, 2021
  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $95 on, Friday, February 5th, 2021
  • Shawn Egan of "Citigroup" Initiated at Strong Buy and Held Target at $90 on, Thursday, November 19th, 2020
Contributing Sources